CuraGen Licenses Seattle Genetics’ ADC Technology
By Business Review Editor
Pharma Deals Review: Vol 2004 Issue 50 (Table of Contents)
Published: 4 Aug-2004
DOI: 10.3833/pdr.v2004.i50.789 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
CuraGen has licensed Seattle Genetics’ proprietary antibody-drug conjugate technology for use with its antibodies for treating cancer...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS